Wall Street brokerages expect OncoSec Medical Incorporated (NASDAQ:ONCS) to announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Zero analysts have provided estimates for OncoSec Medical’s earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.22). OncoSec Medical posted earnings of ($0.39) per share during the same quarter last year, which would indicate a positive year over year growth rate of 41%. The firm is expected to announce its next quarterly earnings results on Thursday, October 12th.

On average, analysts expect that OncoSec Medical will report full year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.02) to ($1.00). For the next year, analysts forecast that the company will post earnings of ($0.97) per share, with EPS estimates ranging from ($1.02) to ($0.91). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow OncoSec Medical.

A number of equities research analysts have recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a report on Friday, September 1st. ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. Dawson James reaffirmed a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a report on Thursday, July 6th. Noble Financial reaffirmed a “buy” rating on shares of OncoSec Medical in a report on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 target price on shares of OncoSec Medical and gave the stock a “buy” rating in a report on Monday, June 12th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $5.33.

OncoSec Medical (ONCS) traded up 0.92% during trading on Friday, reaching $1.09. 161,846 shares of the company’s stock traded hands. The firm’s market capitalization is $23.07 million. The company has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.13. OncoSec Medical has a one year low of $0.88 and a one year high of $2.08.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate OncoSec Medical Incorporated (ONCS) Will Announce Earnings of -$0.23 Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/08/analysts-anticipate-oncosec-medical-incorporated-oncs-will-announce-earnings-of-0-23-per-share.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.